Related Experiment Videos
[A case of macrophage activation syndrome developed with systemic juvenile rheumatoid arthritis]
T Imagawa1, S Katakura, M Mori
1Department of Pediatrics, Yokohama City University School of Medicine.
Abstract:
We reported a child of macrophage activation syndrome (MAS) associated with the course of systemic juvenile rheumatoid arthritis (sJRA). The clinical and laboratory findings in our case was ascribed to the overproduced inflammatory cytokines especially TNF-alpha by activated macrophages. Moreover, macrophage-colony stimulating factor (M-CSF) was also elevated in the active phase of the disease, and decreased in the convalescent phase, indicating that M-CSF can be the most potent stimulator of macrophages to produce inflammatory cytokines. Cyclosporine A along with plasmaexchange and corticosteroid, instead of VP16 or other immunosuppresive agents, was effecting in the management of this severe, life-threatening MAS.
Insights
Macrophage activation syndrome (MAS) in a child with systemic juvenile rheumatoid arthritis (sJRA) was linked to elevated inflammatory cytokines. Macrophage-colony stimulating factor (M-CSF) emerged as a key stimulator in this severe condition.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Hematology
Background:
- Systemic juvenile rheumatoid arthritis (sJRA) can present with severe complications.
- Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory condition.
Observation:
- A pediatric case of MAS associated with sJRA was observed.
- Elevated levels of tumor necrosis factor-alpha (TNF-alpha) and macrophage-colony stimulating factor (M-CSF) were noted during active disease phases.
Findings:
- The study identified overproduced inflammatory cytokines, particularly TNF-alpha, from activated macrophages as the cause of MAS in sJRA.
- Elevated M-CSF levels correlated with disease activity, suggesting its role in stimulating cytokine production.
Implications:
- M-CSF may be a crucial factor in the pathogenesis of MAS in sJRA.
- Cyclosporine A, plasma exchange, and corticosteroids proved effective in managing this severe MAS, offering an alternative to other immunosuppressants.